 | Up a level |
Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter, Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Atallah, Ehab, Collins, Robert, Jr., Kantarjian, Hagop, Jabbour, Elias, Wilhelm, Francois E., Azarnia, Nozar and Silverman, Lewis R. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol., 17 (4). S. 496 - 509. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter L., Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Collins, Robert, Atallah, Ehab, Wilhelm, Francois, Wilhelm, Isabelle E., Azarnia, Nozar, Maniar, Manoj and Silverman, Lewis R. (2014). Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Silverman, Lewis R., Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter L., Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Collins, Robert, Atallah, Ehab, Navada, Shyamala C., Wilhelm, Francois, Azarnia, Nozar and Garcia-Manero, Guillermo (2014). Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020